2004 JAN 15 - (NewsRx.com & NewsRx.net) -- GTC Biotherapeutics, Inc., (GTCB) has completed enrollment into the efficacy study for recombinant human antithrombin III (rhATIII).
The results of the efficacy study will be included in a filing requesting marketing authorization in Europe. A total of 14 patients have been enrolled and treated in this study.
The efficacy study was designed to assess the ability of rhATIII to prevent blood clots in patients that have a hereditary antithrombin deficiency and are giving birth or undergoing a major surgical procedure. GTC expects to file for marketing authorization in Europe by February 2004. The product will be sold …
No comments:
Post a Comment